Margareth Ndomondo-Sigonda

Margareth Ndomondo-Sigonda

Auto-generated profile, based on publicly available information

Margareth Ndomondo-Sigonda

Pharmacology Division, Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of Witwatersrand 2. African Union Development Agency -New Partnership for Africa’s Development

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Globalization and Health
Verified
Journal Article
Open access
PDF file
LRLukas Roth
Lukas Roth
DBDaniel Bempong
Daniel Bempong
JBJoseph B. Babigumira
Joseph B. Babigumira
SBShabir Banoo
Shabir Banoo
ECEmer Cooke
Emer Cooke
JNJude Nwokike
Jude Nwokike
Access to quality-assured medical products improves health and save lives. However, one third of the world’s population lacks timely access to quality-assured medicines while estimates indicate that at least 10% of medicine in low- and middle-income countries (LMICs) are substandard or falsified (SF), costing approximately US$ 31 billion annually. National regulatory authorities are the key government institutions that promote access to quality-assured medicines and combat SF medical products but despite progress, regulatory capacity in LMICs is still insufficient. Continued and increased investment in regulatory system strengthening (RSS) is needed. We have therefore reviewed existing global normative documents and resources and engaged with our networks of global partners and stakeholders to identify three critical challenges being faced by NRAs in LMICs that are limiting access to medical products and impeding detection of and response to SF medicines. The challenges are; implementing value-added regulatory practices that best utilize available resources, a lack of timely access to new, quality medical products, and limited evidence-based data to support post-marketing regulatory actions. To address these challenges, we have identified seven focused strategies; advancing and leveraging convergence and reliance initiatives, institutionalizing sustainability, utilizing risk-based approaches for resource allocation, strengthening registration efficiency and timeliness, strengthening inspection capacity and effectiveness, developing and implementing risk-based post-marketing quality surveillance systems, and strengthening regulatory management of manufacturing variations. These proposed solutions are underpinned by 13 focused recommendations, which we believe, if financed, technically supported and implemented, will lead to stronger health system and as a consequence, positive health outcomes.

21 January 2021 in BMC Public Health
Verified
Journal Article
Open access
PDF file
MNMargareth Ndomondo-Sigonda
Margareth Ndomondo-Sigonda
JMJacqueline Miot
Jacqueline Miot
SNShan Naidoo
Shan Naidoo
Nelson Enos MasotaNelson Enos Masota
Nelson Enos Masota
BNBrian Ng’aNdu
Brian Ng’aNdu
EKEliangiringa Kaale
Eliangiringa Kaale
Background: Limited capacity to regulate medical products is associated with circulation of products which do not meet standards of quality, safety and efficacy with negative public health and economic outcomes. This study focused on assessing the effect of the East African Community (EAC) medicines regulatory harmonization initiative on the capacity of national medicines regulatory agencies, with a focus on registration and inspection systems. Methods: An exploratory mixed-method design using both qualitative and quantitative data to access data from six national medicines regulatory authorities (NMRAs) and the EAC Secretariat. Data was collected using a combination of semi-structured interviews, questionnaires, and checklists for the period 2010/11–2015/16 with 2010/11 data serving as baseline. Heads of NMRAs, regulatory and monitoring and evaluation experts, and the EAC Secretariat Project Officer were enrolled in the study. A set of 14 indicators grouped into 6 categories were used to assess NMRAs performance. Results: Policy and legal frameworks provide a foundation for effective regulation. Collaboration, harmonization, joint dossier reviews and inspections of manufacturing sites, reliance and cooperation are key factors for building trust and capacity among NMRAs. Five out of six of the EAC Partner States have comprehensive medicines laws with autonomous NMRAs. All the NMRAs have functional registration and good manufacturing practice inspection systems supported by regional harmonised guidelines for registration, inspection, quality management and information management systems with four NMRAs attaining ISO 9001:2015 certification. Conclusions: The EAC regulatory harmonization initiative has contributed to improved capacity to regulate medical products. The indicators generated from this research can be replicated for evaluation of similar initiatives across and beyond the African continent and contribute to public health policy.

12 August 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
JMJane H. Mashingia
Jane H. Mashingia
VAVincent Ahonkhai
Vincent Ahonkhai
NANoel Aineplan
Noel Aineplan
AAAggrey Ambali
Aggrey Ambali
AAApollo Angole
Apollo Angole
DMDavid Mukanga
David Mukanga
Jane H. Mashingia and colleagues reveal the progress made to date for the East African Community Medicines Regulatory Harmonization initiative.

1 January 2018 in Medical Research Archives
Verified
Journal Article
Open access
PDF file
MNMargareth Ndomondo-Sigonda
Margareth Ndomondo-Sigonda
JMJacqueline Miot
Jacqueline Miot
SNShan Naidoo
Shan Naidoo
AAAggrey Ambali
Aggrey Ambali
ADAlexander Dodoo
Alexander Dodoo
HMHlazo Mkandawire
Hlazo Mkandawire
The African Medicines Regulatory Harmonization Initiative (AMRH) has contributed to reduce marketing authorization timelines in East African Community and the Southern African Development Community member states. Challenges still exist in using the outcome of the regional joint dossier review processes for national decision making processes by the national medicines regulatory agencies. Progress in domestication of the African Union Model Law on Medical Products Regulation by twelve countries provides basis for improving regulatory systems. This is coupled by the designation of eleven regional centers of regulatory excellence which will ensure sustainable training programmes and subsequent increase in Africa’s regulatory workforce. The Biennial Scientific Conferences on Medical Products Regulation in Africa is a strategic platform for knowledge and ideas exchange among key stakeholders in the pharmaceutical sector. The ongoing alignment of the African Vaccines Regulators Forum, the Network of Medicines Control Laboratories in Sub-Saharan Africa, Pan African Harmonization Working Party on the regulation of medical devices and diagnostics, the planned establishment of a forum for blood and blood with AMRH serves as a solid foundation for establishment of the African Medicines Agency (AMA). AMA will be a key driver to remove technical barriers for trading among the region countries by contributing to the continental socio-economic development agenda.

12 August 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
HSHiiti Sillo
Hiiti Sillo
AAAggrey Ambali
Aggrey Ambali
SASamvel Azatyan
Samvel Azatyan
CCChimwemwe Chamdimba
Chimwemwe Chamdimba
EKEliangiringa Kaale
Eliangiringa Kaale
VAVincent Ahonkhai
Vincent Ahonkhai
Hiiti Sillo and colleagues reveal how the East African Community’s Medicines Regulatory Harmonization initiative improves access to important medicines in Africa.

12 August 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
MAMawien Arik
Mawien Arik
EBEmmanuel Bamenyekanye
Emmanuel Bamenyekanye
AFAdam Fimbo
Adam Fimbo
JKJoseph Kabatende
Joseph Kabatende
AKAgnes Sitta Kijo
Agnes Sitta Kijo
TDThomas Delano
Thomas Delano
Margareth Ndomondo-Sigonda outlines future challenges for the East African Medicines Regulatory Harmonization initiative.